

# Master Investor 2019

fastforward ▶



# Disclaimer

This presentation (“Presentation”) is being provided to you (the “Recipient”) by FastForward Innovations Limited (the “Company” or “FastForward”) for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company. The content of this Presentation has not been approved by an authorised person for the purposes of Section 21(2)(b) of the Financial Services and Markets Act 2000. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This Presentation is not an admission document or an advertisement and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any ordinary shares of the Company (“Shares”) in the United States or any other jurisdiction where the sale of Shares is restricted or prohibited. Neither this Presentation, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any Shares. Whilst this Presentation has been prepared in good faith, no representation or warranty, express or implied, is given by or on behalf of the Company, its respective directors and affiliates or any other person as to the accuracy or completeness of the information or opinions contained in this Presentation and no responsibility or liability whatsoever is or will be accepted by the Company, its respective directors and affiliates or any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith. Any such liability is expressly disclaimed. The promotion of the Shares and the distribution of this Presentation in the United Kingdom are restricted by law. Accordingly, this Presentation is directed only at (i) persons outside the United Kingdom to whom it is lawful to communicate it, or (ii) persons having professional experience in matters relating to investments who fall within the definition “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (iii) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order and any other persons who fall within other applicable exemptions under the Order, provided that in the case of persons falling into categories (ii) and (iii), the communication is directed only at persons who are also “qualified investors” as defined in Section 86 of the Financial Services and Markets Act 2000 (together, “Relevant Persons”). Any investment or investment activity to which this Presentation relates is available only to, and will be engaged in only with, Relevant Persons. This Presentation must not be acted on or relied on by persons who are not Relevant Persons. You represent and agree that you are a Relevant Person. The Recipient is responsible for obtaining such legal and tax advice as it considers appropriate in connection with any proposed investment in Shares. The Recipient acknowledges that it is not relying on any legal or tax advice from the Company and any general statement by the Company regarding any matter of law or its tax status is not oriented towards any specific Recipient. The Recipient is aware that under certain circumstances, with respect to ownership of Shares, there may be detrimental tax treatment for U.S. taxpayers, as a result of the Passive Foreign Investment Company (the “PFIC”) and Controlled Foreign Corporation (“CFC”) rules if the Company is classified as a PFIC, CFC or both. Further, the Recipient understands that, at this time, the Company does not intend to make special accommodations regarding its financial information to assist holders with their U.S. tax obligations.

The Company does not intend to offer the Shares into the U.S. through any public means and similarly does not intend to register the Shares with the U.S. Securities and Exchange Commission and therefore any offer and sale into the U.S. will be required to be in compliance with an exemption or exemptions from various state and federal laws regarding securities registration. Further, the Company intends to restrict any offer and sale of Shares and its business activities to remain in compliance with exemptions from the requirement to register as an investment company in the United States. However, if the Company is unable to maintain compliance with the aforementioned exemptions and it was required to seek registration, it would likely have a material detrimental effect on the Company. The Company is not responsible to the Recipient for providing regulatory and legal protections afforded to customers (as defined in the rules of the Financial Conduct Authority) nor for providing advice in relation to the contents of this document on any matter, transaction or arrangement referred to in it. Neither of the Company nor any of its respective directors, officers or employees makes any representation or warranty, express or implied, as to the accuracy or completeness of the information or opinions contained in this Presentation. Nothing in this Presentation is, or should be relied on as, a promise or representation as to the future. This document contains forward-looking statements, which reflect the views of the Company with respect to, among other things, the Company’s operations and investments. These forward-looking statements are identified by the use of words such as “believe”, “expect”, “potential”, “continue”, “may”, “will”, “should”, “seek”, “approximately”, “predict”, “intend”, “plan”, “estimate”, “anticipate” or other comparable words. These forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Should any assumptions underlying the forward-looking statements contained in this Presentation prove to be incorrect, the actual outcome or results may differ materially from outcomes or results projected in these statements. The Company is under no obligation to update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law or regulation. The distribution of this Presentation in certain non-UK jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restrictions. Any such distribution could result in a violation of the law of such jurisdictions. Neither this document nor any copy of it may, subject to certain exemptions, be taken or transmitted into Australia, Canada, Japan, South Africa, Singapore, or the U.S. or distributed to these countries or to any national, citizen or resident thereof or any corporation, partnership or other entity created or organised under the laws thereof. This Presentation does not constitute or form any part of an offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe or otherwise acquire, any Shares in any jurisdiction. Issued by FastForward Innovations Limited. Registered Office at 11 New Street, St Peter Port, Guernsey GY1 2PF. The Company is an authorised closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended and the Authorised Closed-Ended Investment Schemes Rules 2008 issued by the Guernsey Financial Services Commission (“GFSC”).





**FastForward invest in innovative life science companies and emerging technologies that we believe will shape the future.**



# Directors

## **Lorne Abony - 10.55%\***

Lorne Abony is a well-known technology and media entrepreneur whose many successful tech ventures include the 2001 cofounding of FUN Technologies (“FUN”), an AIM listed company. In 2004 as CEO of FUN, Mr. Abony became the youngest CEO of a listed company on the Toronto Stock Exchange (TSX), and he sold FUN in 2006 to Liberty Media for CAD\$484 million. Mr. Abony was the Chief Executive officer of TSX-V listed Nuuvera Inc a global cannabis company founded on Canadian principles, which was subsequently sold to Aphria in 2018.

## **Jim Mellon - 11.58%\***

Jim is a visionary entrepreneur with a flair for identifying emerging global trends. Most notably and very publicly, he predicted the credit crunch of 2007-08 in a book entitled "Wake Up! Survive and Prosper in the Coming Economic Turmoil". In addition, Jim published “Fast Forward: The Technologies and Companies Shaping our Future”, a book setting out a vision for the future shared by FastForward and its Directors (and providing the inspiration for the name of the company!). Jim's wealth of knowledge and vast experience allows FastForward to capitalise on sound opportunistic investments ideas. Through these investments, Jim has built a worldwide business empire.

# Directors

## Ian Burns

Ian Burns is a fellow of the Institute of Chartered Accountants in both England and Wales. He is the founder and Senior Executive Director of Via Executive Limited, a specialist management consulting company and the Managing Director of Regent Mercantile Holdings Limited, a privately owned investment company.

## Lance De Jersey

Lance De Jersey is member of the Institute of Chartered Secretaries and Administrators and Institute of Directors. He previously headed Partners Group's Guernsey office and has over eight years experience in private equity investment administration and management. In the past, Mr De Jersey has owned and operated retail franchises, marketed and sold small businesses as a business broker and worked as a financial adviser in New Zealand. He is former secretary and vice chairman of the Channel Island Private Equity and Venture Capital Association.

## Ed McDermott

Ed McDermott has over 10 years' experience in the management, financing and development of small companies he has broad experience in a number of sectors including natural resources, technology, financial services, retail and leisure. Ed is currently UK MD of EMMAC Life Sciences and Non-Executive Director of Emmerson Plc. He has previously served as a Director of AIM listed Stellar Resources Plc and Noricum Gold Ltd.



# Stock Overview

166m


## Shares in issue

**£15.75**


## MCAP as of 1/4/19

9.75p

Share price as of 1/4/19



# Timeline



# Investment Philosophy

*“As a board we are constantly working with investee management teams to maximize shareholder value but much of this work must be carried out beyond the glare of publication to the wider world.”* HY Report, 2018

- FastForward believes that attractive investment returns can be generated from investing in emerging sectors that will shape the future.
- We invest in visionary entrepreneurs developing innovative projects that solve problems in their industries.





# Investment Approach

1

Leverage years of experience and expertise in the FastForward management team and identify opportunities in emerging life sciences and technologies.

2

Use the reputation and networks of the FastForward management team, find and recruit world-class management teams to execute on bringing products to market.

3

Rigorous and disciplined due diligence is applied to market analysis to ensure market entry and sizing potential.

4


FastForward team then creates a plan of action to help disrupt and innovate in a sector.



# Capitalising on the life sciences revolution

*'Conclusive or substantial evidence that cannabis or cannabinoids are effective: a) for the treatment of chronic pain in adults (cannabis); b) as treatment for chemotherapy-induced nausea and vomiting (oral cannabinoids) c) for improving patient-reported multiple sclerosis spasticity symptoms (oral cannabinoids)' - Chief Medical Officer for England and Chief Medical Advisor, Professor Dame Sally Davies*

*'Cannabis is becoming increasingly understood that it is a very interesting and versatile medicine with much less toxicity than some of the pharmaceutical products it replaces' - Dr. Lester Grinspoon (Professor at Harvard Medical School)*



Horizons Marijuana Life Sciences ETF (HMMJ.TO)



# Medical Cannabis, Cannabinoids and Wellness



€123bn

Projected value of Europe's cannabis market by 2028



40+

European countries with legal medical cannabis or exploring medical cannabis



Germany

Likely to become largest medical cannabis market in Europe

*How will FastForward capitalise on this exciting industry?*

1. **Technical 'know-how'** - executed similar strategy with Nuuvera
2. **Strong network in the industry** - access to multiple cannabis deals
3. **Significant industry experience** - rigorous due diligence and selectivity



# Portfolio Summary

## Life Sciences



**EMMAC**  
LIFE SCIENCES PLC

JUVENESCENCE



PulseFlow<sup>TM</sup>

## Technology



**FACTOM**<sup>TM</sup>

**LEAP**  
VIRTUAL GAMING

**YOOYA** ▶

vemo  
EDUCATION

vogogo<sup>TM</sup>



# Portfolio Details\*

Holding	Share Class	Category	# Shares held at 30 September 2018	Valuation at 30 September 2018 (£ '000)
<b>Fralis LLC (Leap Gaming)</b>	Units	Gaming	1,512	4,838
<b>Intensity Therapeutics</b>	Series A Preferred	Life Sciences	250,000	822
<b>Intensity Therapeutics</b>	Series B Preferred	Life Sciences	38,458	173
<b>Juvenescence</b>	Ordinary	Life Sciences	128,205	1,533
<b>The Diabetic Boot Company</b>	Ordinary	Life Sciences	25,978	-
<b>Factom</b>	Series Seed	Blockchain Tech	400,000	548
<b>Factom</b>	SAFE Advance	Blockchain Tech	-	4,599
<b>Vemo Education</b>	Pref Series Seed-1 Pref Series Seed-2	Edtech	3,527,059	276
<b>Vogogo</b>	Convertible Debenture Units	Blockchain Tech	23,000	1,287
<b>Yooya Media</b>	Series Seed Preferred	Media and Content	27,255	1,456
<b>Total investments value</b>				<b>15,532</b>

\*per half-yearly report at 30 September 2018



## Portfolio Additions (post HY report)

Holding	Share Class	Category	# Shares held	Acquisition value (£ '000)
EMMAC Life Sciences	Ordinary	Life Sciences	6,666,667	2,000

- EMMAC is a European independent medical cannabis company co-founded by Ed McDermott and Antonio Costanzo.
- EMMAC is led by Chief Executive Officer Antonio Costanzo, the former Head of International Development of Nuuvera.
- EMMAC has a partnership agreement with Imperial College, London, on a research collaboration to investigate mechanisms of action of cannabis-based medicinal products.
- EMMAC has recently completed the acquisitions of Medalchemy, a technology based research and manufacturing company with GMP-certified laboratory facilities in Alicante, Spain, and the "*Blossom*" brand of CBD / Wellness products in Switzerland.



# Summary

- FastForward has adopted a venture capital approach, focused on early stage investments in private emerging companies which the directors have identified as having significant upside.
- Strong focus on Life Sciences and Technology sectors.
- Highly experienced management team with multiple successes in relevant sectors.
- Currently the only company listed on the LSE with a direct investment in the medical cannabis sector.

# Thank you

[info@fstfwd.co](mailto:info@fstfwd.co)

**FastForward Innovations Limited**  
**11 New Street**  
**St Peter Port**  
**Guernsey**  
**GY1 3EG**

[www.fstfwd.co](http://www.fstfwd.co)

